• Profile
Close

Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): A randomized, double-blind, active-comparator-controlled phase 3 trial

The Lancet Aug 22, 2019

Reich K, Gooderham M, Thaçi D, et al. - Via IMMvent—a phase 3, randomized, double-blind, active-comparator-controlled trial that was completed at 66 clinics in 11 countries and involved 605 adults with moderate-to-severe chronic plaque psoriasis—researchers compared the efficiency and safety of risankizumab with adalimumab in patients with moderate-to-severe plaque psoriasis. In patients with moderate-to-severe plaque psoriasis, risankizumab demonstrated significantly higher efficiency than adalimumab in providing skin clearance. For patients who switched from adalimumab to risankizumab, no additional safety concerns were noted. Moreover, treatment with risankizumab offered flexibility in the long-term treatment of psoriasis.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay